Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Example Prior Systemic Therapy Statement — Tamoxifen Adjuvant Hormonal Therapy

Raw xml | Download

<MedicationStatement xmlns="http://hl7.org/fhir">
  <id value="PriorSystemicTherapyStatementExample"/>
  <meta>
    <profile
             value="https://nshr-uat.sha.go.ke/fhir/StructureDefinition/nccp-prior-systemic-therapy-statement"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: MedicationStatement PriorSystemicTherapyStatementExample</b></p><a name="PriorSystemicTherapyStatementExample"> </a><a name="hcPriorSystemicTherapyStatementExample"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-nccp-prior-systemic-therapy-statement.html">NCCP Prior Systemic Therapy Statement</a></p></div><p><b>status</b>: Completed</p><p><b>category</b>: <span title="Codes:{https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs HORMONAL-THERAPY}">Hormonal Therapy</span></p><p><b>medication</b>: <span title="Codes:{https://nshr-uat.sha.go.ke/fhir/CodeSystem/generic-products-cs TAMOXIFEN}">Tamoxifen</span></p><p><b>subject</b>: <a href="Patient-example-patient.html">Mary Wanjiku  Female, DoB: 1975-06-15</a></p><p><b>effective</b>: 2018-03-01 --&gt; 2023-02-28</p><p><b>reasonReference</b>: <a href="Condition-example-condition.html">Condition C50 — Malignant neoplasm of breast</a></p><p><b>note</b>: </p><blockquote><div><p>Completed 5 years of adjuvant tamoxifen. Switched to letrozole following menopause in 2021.</p>
</div></blockquote></div>
  </text>
  <status value="completed"/>
  <category>
    <coding>
      <system
              value="https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs"/>
      <code value="HORMONAL-THERAPY"/>
      <display value="Hormonal Therapy"/>
    </coding>
  </category>
  <medicationCodeableConcept>
    <coding>
      <system
              value="https://nshr-uat.sha.go.ke/fhir/CodeSystem/generic-products-cs"/>
      <code value="TAMOXIFEN"/>
      <display value="Tamoxifen"/>
    </coding>
  </medicationCodeableConcept>
  <subject>🔗 
    <reference value="Patient/example-patient"/>
  </subject>
  <effectivePeriod>
    <start value="2018-03-01"/>
    <end value="2023-02-28"/>
  </effectivePeriod>
  <reasonReference>🔗 
    <reference value="Condition/example-condition"/>
  </reasonReference>
  <note>
    <text
          value="Completed 5 years of adjuvant tamoxifen. Switched to letrozole following menopause in 2021."/>
  </note>
</MedicationStatement>